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Recently an article published by Ahmadi et al, entitled “whether vitamin D3 is effective in reducing proteinuria in type 2 diabetic patients? (1). In a randomized double 
blinded parallel groups clinical trial, 51 diabetic individuals 
with proven diabetic kidney disease and vitamin D deficiency/
insufficiency and stable hypertension, dyslipidemia, and 
hyperglycemic treatment were selected. Patients received oral 
vitamin D3 (pearl 50000 IU) or placebo one pearl every week 
for 12 weeks. Patients were assessed at baseline and 12 weeks 
after intervention from the point of 25(OH)D level, and urine 
albumin/creatinine ration (1). They assessed, plasma 25(OH)D 
level prior and after the intervention after and urine albumin/
creatinine ratio. In their study, there was not a decrease in 
proteinuria in patients who obtained vitamin D for a period 
of 3 months (1). Diabetic nephropathy is a major risk of end-
stage kidney failure and is associated with greater morbidity 
and mortality, predominantly with augmented cardiovascular 
disease (2,3). Many complex factors relate to the progression of 
diabetic nephropathy (4,5). Current investigations have focused 
on the optimization of renin-angiotensin system blockade in 
patients with nephropathy of diabetes using combinations of 
drugs that target this pathway (6-8), however further studies 
have focused on the potential of new therapies that either 
target various pathways up-regulated by hyperglycemia or 
other targets believed to promote progression of diabetic 
nephropathy for example the endothelin system, inflammation 
and vitamin D receptors (9-11). Up to now, various evidence 
supports, vitamin D as a negative regulator of the circulating 
and local tissue renin-angiotensin system, while the renin-
angiotensin system have a critical role in the physiology of 
sodium and volume homeostasis (6-11). Excess activity of 
the renin-angiotensin system is associated with high blood 
pressure, kidney disease and diabetes. Indeed it is possible that, 
the most important putative mechanisms associating vitamin 
D to blood glucose control is its regulation of the renin-
angiotensin system suppression of renin biosynthesis (2-8). It 
seems that treatment with vitamin D reduced the urinary urine 
albumin/creatinine ratio level by suppressing the compensatory 
renin increase in diabetic nephropathy (2-8). These beneficial 
consequences might be contributed to suppressed renal 
expression of renin and transforming growth factor beta 
(TGF-β) which may or may not be angiotensin II dependent 
(3-10). Recent studies have shown that low 25(OH)D3 levels 
are common in  individuals with albuminuria. Thus, the anti-
proteinuric efficacy of vitamin D in diabetic kidney disease is 
mediated by vitamin D receptor activation (4-11). More recent 
studies suggests that the effect of vitamin D receptor activation 
is partly that of negatively regulating renin-angiotensin system, 
which plays a significant role in the development of diabetic 
kidney disease (4-11). It is possible that, non-positive result on 
diminution of proteinuria by vitamin D therapy in the study of 
Ahmadi et al. may be due to short period of treatment. Also, 
in their study, it should be better to dissociate males from 
females and then analyze the data distinctly, while Houng et al. 
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found that mean 25(OH)D3 concentrations were meaningfully 
lower in females than in males (12). In fact, a low vitamin D 
status was more closely associated with micro-albuminuria in 
males than in females (2-8,13). Limitations of study conducted 
by Ahmadi et al, need to be considered too. The sample size 
was small. In addition, limited duration of exposure to drug, 
as mentioned. Importantly, the season may affect vitamin D 
concentrations, and might also influence treatment outcome 
a factor that is very difficult to control. In addition, the best 
effective dose needs further exploration and finally, lack of 
evaluation of parathormone levels, while a bulk of evidences, 
revealed the positive association of parathyroid hormone and 
level blood pressure as an aggravating factor for diabetic kidney 
disease (2-9,12-14). Thus the negative result on reducing the 
proteinuria in diabetic kidney disease, should not discourage its 
use. We suggest, more prospective interventional studies with 
larger duration with control of confounders to better found this 
aspect of diabetic patients.
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